Purpose of review Although historically Marfan syndrome (MFS) has always been considered as a condition caused by the deficiency of a structural extracellular matrix protein, fibrillin-1, the study of Marfan mouse models and Marfan-related conditions has shifted our current understanding to a pathogenic model that involves dysregulation of the cytokine-transforming growth factor beta (TGF-b) signaling.
INTRODUCTION
In 1896, Antoine-Bernard Marfan described for the first time a child with a syndrome that now bears his name: Marfan syndrome (MFS) [1] . It took about a century to find the genetic cause of this inheritable connective tissue disorder. In 1991, Dietz et al. [2] identified the first mutations in the FBN1 gene, coding for fibrillin-1, an important extracellular matrix protein. The disease is mainly characterized by skeletal (overgrowth), ocular (lens dislocation or ectopia lentis) and cardiovascular (aortic aneurysm/ dissection and mitral/aortic valve insufficiency) manifestations. Over the last decade, significant progress has been made in the understanding of the pathogenesis of this condition and MFS has served as a paradigm for the study of the pathogenesis of thoracic aortic aneurysms in general. Through the study of different mouse models [3] [4] [5] and the identification of the molecular cause of the MFS-like condition Loeys-Dietz syndrome (LDS) (TGFbR1/2; transforming growth factor beta receptor 1/2 gene [6] ), it became clear that fibrillin-1 is not only an important microfibrillar structural molecule but also serves as a regulator of TGF-b (transforming growth factor beta) signaling. Over the last few years, important progress has been made in the further delineation of the MFS differential diagnosis, the understanding of the role of TGF-b signaling and the treatment strategies.
CLINICAL DIAGNOSTIC CRITERIA: FROM OLD TO NEW
Over the past decades, the clinical diagnostic criteria for MFS have evolved with new clinical and molecular insights. The original Berlin criteria [7] were reshaped into the Ghent nosology (classification) [8] taking into account the need for higher specificity and newly identified clinical findings such as dural ectasia. In 2010, Loeys et al. [9] defined a new set of criteria for the diagnostic decision-making process in MFS. Overall, this revised nosology gave a more central role to the cardiovascular complications (aortic aneurysm and dissection) and a higher weight to molecular testing of the FBN1 gene and other relevant genes (such as TGFbR1/2, COL3A1, ACTA2). The diagnosis of MFS in a proband without family history can be made on the basis of the presence of one of four basic rules: aortic root dilatation (z-score !2) and ectopia lentis, aortic root dilation with an FBN1 mutation, aortic root dilation with sufficient systemic findings (score of 7 or more on the systemic scale; for details see Table 1 or [9] ), or finally ectopia lentis with an FBN1 mutation that has been associated with aortic root dilation. In probands with a family history, similar rules have been developed (Table 1) . Moreover, the nosology study offers an extensive overview of the differential diagnoses and a guide to the management of MFS and MFS-like conditions. Over the last year, several studies have been published on the concordance of the old and revised nosology for MFS. Although the number of patients for a given diagnosis differed slightly, the level of agreement between both nosologies was found to be very high [10 & ,11-13] . In general, the correlation with molecular testing was found to be high, but some criticism has been raised on the use of the aortic z-scores, especially in adults [11,14 & ]. Also, the systemic score will need further validation [14 & ].
KEY POINTS
Tissue-specific and cell-specific dysregulation of TGF-b signaling in a specific developmental context explains the presence or absence of aneurysm formation in these different conditions.
Although until recently most studies of MFS have focused on canonical TGF-b signaling, growing evidence now shows that noncanonical signaling pathways also have an important role in aneurysm development.
In addition to the angiotensin II type 1 receptor blocking effect, losartan also has an inhibiting effect on TGF-b signaling by reducing both the total and active amount of TGF-b. 
FBN1 UNVEILS ITS SECRETS: FROM THIN TO THICK, FROM TALL TO SHORT
Although in general FBN1 mutations cause disorders with clinical phenotypes in the MFS spectrum (e.g. ectopia lentis syndrome, marfanoid body habitus, familial thoracic aortic aneurysm with mild systemic findings), three major surprises have emerged (Table 2) . First, in a genome-wide association study on sporadic thoracic aortic aneurysm/dissection (STAAD) patients, several single-nucleotide polymorphisms (SNPs) at the 15q21.1 locus were found to be associated [15 && ]. These SNPs map within a large region of linkage disequilibrium encompassing the FBN1 gene. As such, this study suggests that common genetic variants at 15q21.1, probably acting via FBN1, may be involved in the development of STAAD. The authors did not provide evidence for deficient fibrillin-1 protein or altered fibrillin-1 expression in these STAAD patients and it remains unclear why these patients fail to present systemic features of MFS. Further studies will be necessary to confirm a putative common pathogenesis of aortic disease in MFS and STAAD.
Second, Loeys et al. [16] found domain-specific FBN1 mutations in stiff skin syndrome (SSS), a congenital form of scleroderma. All affected SSS patients lacked the skeletal, ocular and cardiovascular findings of MFS, but presented with congenital thickened skin and relatively short stature. Because the 'tight skin' (Tsk) mouse is heterozygous for a naturally occurring in-frame Fbn1 (fibrillin-1) duplication, a role for FBN1 mutations in SSS was hypothesized. Indeed, all these patients had a missense mutation in FBN1, either substituting or creating a cysteine residue in the fourth TGF-b-binding protein-like motif of fibrillin-1, encoded by exons 37 and 38. These cysteines are essential for proper TGF-b-binding protein-like motif folding and the unique feature of TGF-b-binding protein-like motif 4 of fibrillin-1 is that it is the only domain that encodes an RGD (Arg-Gly-Asp) sequence. This sequence is known to mediate cell-matrix interactions via integrin binding. Additional electron microscopy, immunohistochemistry and immunoblotting experiments suggested that in SSS a loss of longitudinal growth and increased lateral growth of microfibrillar aggregates occur. Additionally, a role for increased TGF-b signaling was suggested. Both events are plausibly explained by integrin-mediated matrix-cell attachments [16] . The relevance of this pathogenic mechanism to classic scleroderma warrants further investigation. Interestingly, SMAD4 mutations were recently identified as the cause of Myhre syndrome, a condition with short stature and a body habitus that is reminiscent of SSS [17 && ]. [20] . Importantly, a direct interaction between ADAMTSL2 and FBN1 was demonstrated, suggesting a disruption of this interaction as the underlying mechanism of the geleophysic and acromicric dysplasia phenotypes. The ADAMTS family encompasses a group of proteins containing ADAMTSL1 repeats. These proteins have a role in extracellular matrix degradation and turnover [19 && ]. The finding of similar enhancement of TGF-b signaling and microfibrillar structural changes in acromicric and geleophysic dysplasia with FBN1 or ADAMTSL2 mutations further supports the functional link between the TB5 domain and ADAMTSL2. These observations illustrate nicely the tissue dependence and the complexity of the TGF-b pathways and their various levels of regulation. It seems plausible to assume that tissue-specific and cell-specific dysregulation of TGF-b signaling in a specific developmental context explains the absence of aneurysm formation in these different conditions. Further studies will be needed in order to understand how FBN1 mutations can trigger either tall stature, arachnodactyly and hyperlaxity (MFS) or severe short stature, short hands and stiff joints (acromicric dysplasia, geleophysic dysplasia and SSS).
Since the discovery of the LDS [6, 21] , increasing evidence has emerged for the existence of a group of TGF-b vasculopathies. Not only in LDS, but also in fibulin-4-related autosomal recessive cutis laxa [22] , arterial tortuosity syndrome and nonsyndromic forms of thoracic aortic aneurysm [22] , the role of TGF-b signaling as a final common pathway in the pathogenesis of aortic aneurysm has emerged (for review see [23 & ] described osteochondritis dissecans in about half of the patients, mostly affecting the medial femur condyle. More than 90% of the patients had intervertebral disc degeneration, most prominent in the cervical and lumbar spine. Finally, nearly all SMAD3 mutation positive patients had osteoarthritis of the knee, spine, hand or foot.
AORTIC ANEURYSM PATHOGENESIS: FROM CANONICAL TO NONCANONICAL TRANSFORMING GROWTH FACTOR BETA-SIGNALING
As outlined in the Introduction section, there has been a major shift in our understanding of the pathogenesis of MFS. The function of fibrillin-1 has evolved from a structural extracellular matrix protein to an important regulator of TGF-b homeostasis. Although, until recently, most studies of MFS have focused on canonical TGF-b signaling, growing evidence now shows that noncanonical signaling pathways such as those involving the mitogen-activated protein kinases (MAPKs) also have an important role in aneurysm development (Fig. 1) . First, it was demonstrated that haploinsufficiency for Smad4, a mediator of canonical signaling, improves lung and muscle disorder in a MFS mouse model, but unexpectedly leads to synthetic lethality due to aortic dissection [25 && ]. Marfan mice also showed increased TGF-b-dependent activation of extracellular signal-regulated kinase (ERK1/2) cascades, neither of which was attenuated or enhanced after Smad4 targeting. Instead, the Smad4/Fbn1-deficient mice showed unique activation of the Jun N-terminal kinase (JNK) MAPK and the combined deficiency of Smad4 and Fbn1 was fully rescued by a JNK antagonist. Aortic protection was also seen in MFS mice treated with a JNK antagonist [25 && ]. Second, it was observed in aortas of fibrillin-1-deficient mice that TGF-b-dependent and angiotensin II type 1 receptor (AT1R)-dependent activation of ERK1 and ERK2 was involved in the pathogenesis of aneurysm formation. Further evidence for their importance was obtained from the abrogation of pathological aortic root growth after treatment with a specific ERK inhibitor [26 && ]. Overall, these data suggest that noncanonical TGF-b signaling is a prominent driver of aneurysm progression in MFS, and that ERK and JNK are additive and interchangeable in this process.
TREATMENT STRATEGIES: FROM BETA-BLOCKER TO ANGIOTENSIN RECEPTOR BLOCKER
The current gold standard for treatment of aortic aneurysm in MFS is the preventive administration of beta-blockers. Although it is generally accepted that beta-blockers slow down the aortic root enlargement, they do not prevent surgery at a later age. Based on the insights derived from the study of aortic aneurysms in the Marfan mouse models, it was hypothesized that inhibition of TGF-b signaling might offer a better long-term outcome. Proof of principle was obtained by treating Marfan mice with TGF-b-neutralizing antibody by intraperitoneal injection [3] . The TGF-b-neutralizing antibody blocked the growth of the aortic root. Because of the lack of feasibility of lifelong 2-weekly infusions with TGF-b-neutralizing antibodies, losartan was considered as an attractive alternative. In addition to the angiotensin II type 1 receptor blocking effect, losartan also has an inhibiting effect on TGF-b signaling, by reducing both the total and active amount of TGF-b. In a placebo-controlled trial of Marfan mice, losartan had a superior effect compared with atenolol titrated for the same hemodynamic effect. Not only did losartan-treated mice show a complete arrest of the aortic growth, but also the histology of elastic fibers in the aortic wall was indistinguishable from those of wild-type mice. In a preliminary observational study, 17 pediatric MFS patients with progressive aortic enlargement despite optimal medical therapy were given an angiotensin receptor blocker (ARB) agent and were followed for 12-42 months [27] . Patients had a significant decrease in rate of change of aortic root dimensions after starting the ARB therapy, from a mean (AESD) of 3.57 AE 2.95 mm per year on prior medical therapy to 0.50 AE 0.82 mm per year on ARBs. No difference in heart rate or blood pressure was measured between treatments, indicating that these protective effects achieved with ARBs were likely including TGF-b antagonism. This study provides the first evidence for a significant benefit of ARB use over current therapies in reducing aortic root dilation in severe pediatric MFS.
This preliminary study, along with the mouse data, has led to the initiation of a large, randomized clinical trial in MFS patients. This trial, supported by the Pediatric Heart Network through the US. National Heart, Lung and Blood Institute, had included a total of 608 patients in February 2011 and compares atenolol with losartan for a 3-year treatment [28] . Meanwhile, nearly a dozen additional trials with different designs and inclusion criteria have been initiated in Belgium, France, Italy, the Netherlands, Taiwan and the United Kingdom [29] [30] [31] [32] . Although these different trials might reveal answers to different questions, some concerns have been raised about the dosing and power of some of the trials [14 & ]. Eventually, a meta-analysis of trials with similar design can be performed.
CONCLUSION
The study of MFS mouse models and the identification of the genetic basis of MFS-related conditions have revealed a key role for TGF-b signaling in the pathogenesis of aortic aneurysms. The complex interplay of canonical and noncanonical TGF-b signaling still needs further exploration, but reduction in the overall TGF-b signaling through the use of ARBs seems an excellent therapeutic mechanism. Multiple clinical trials are ongoing to validate preliminary results in MFS mouse models and small human trials.
